Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ENEnsysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC)

NASDAQ Capital Market · Currency in USD
$0.47 ▼ -0.04 (-7.93%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.47 ▲ +0.00 (+0.83%)
After hours: Oct 23, 7:56 PM ET

Summary

Previous Close
$0.51
Open
$0.52
Day's Range
$0.47 – $0.52
52 Week Range
$0.23 – $2.26
Volume
237,132
Avg. Volume
11,524,489
Market Cap
$9.15M
Beta (5Y Monthly)
1.02
PE Ratio (TTM)
--
EPS (TTM)
-$0.97
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Ensysce Biosciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
9
CEO
D. Lynn Kirkpatrick

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.12 · Revenue est. $1.20M
DateEst.Actual
Aug 13, 2026-$0.20-$0.20Beat
May 15, 2026-$0.73-$0.52Beat
Mar 30, 2026-$1.26-$0.75Beat
Nov 14, 2025-$0.85-$1.29Miss
Aug 13, 2025-$1.02-$0.79Beat
May 13, 2025-$3.02-$1.39Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ENSC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.